DISCLAIMER
Information contained in this Presentation is the property of the Company. It is made available strictly for
the purposes of providing background information. Neither the communication of this Presentation nor
any part of its contents is to be taken as any form of commitment on the part of the Company to
proceed with any transaction. This Presentation does not constitute, or form part of, any offer or invitation
to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company,
nor shall it, or the fact of its communication, form the basis of, or be relied upon in connection with, or act
as any inducement to enter into, any contract or commitment whatsoever with respect to such securities.
The communication of this Presentation in or to persons in certain jurisdictions may be restricted by law
and persons who may receive communication of this Presentation should inform themselves about, and
observe, any such restrictions in advance of communication to them of this Presentation. Neither the CSE
nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this
Presentation.
The material contained in this presentation is provided solely for your general knowledge and is not
intended to be a comprehensive review of all matters and developments concerning Breathtec or its
affiliates. Breathtec has taken all reasonable care in producing the information contained in this
presentation. This information may still contain technical or other inaccuracies, omissions, or typographical
errors, for which Breathtec assumes no responsibility. Breathtec makes no representation or warranty
regarding, and assumes no responsibility for, the use, validity, accuracy, completeness, reliability or
currency of any claims, statements or information in this presentation.
To the extent permitted by law, Breathtec Biomedical Inc. and its employees, agents and consultants
exclude all liability for any loss or damage arising from the use of, or reliance on, any such information,
whether or not caused by any negligent act or omission.
Statements in this presentation other than purely historical information, including statements relating to
Breathtec's future plans, objectives or expected results, constitute forward-looking statements. Forwardlooking statements are based on numerous assumptions and are subject to the risks and uncertainties
inherent in Breathtec¹s business, including risks inherent in early stage start up ventures and development.
As a result, actual results may vary materially from those described in the forward-looking statements.
Breathtec disclaims any obligation to update any forward-looking statements.
This presentation was prepared to assist interested parties in making their own assessment of Breathtec
and its business plans and does not purport to contain all of the information that a prospective investor
may desire. In all cases, interested parties should conduct their own investigation and analysis of the
Company, its assets and the information provided in this presentation. Any and all statements, forecasts,
projections and estimates contained in this presentation are based on management¹s current knowledge
and no representation or warranty is made as to their accuracy and/or reliability.
IF A FINGERPRINT CAN TELL
SOMEONE WHO YOU ARE,
A "BREATH PRINT" COULD REVEAL HOW
YOU'RE DOING.
§ 
Anything in your body that is eventually in the blood can
be measured in your breath.
§ 
BreathTec offers a non-invasive, alternative medical
testing solution for various health-related concerns
including cancers, liver disease, kidney failure, diabetes,
asthma and tuberculosis.
§ 
These diseases and more all have a distinctive signature
in the breath which can be distinguished using BreathTec
Bio Medical
BREATH ANALYSIS
ADVANTAGE
§ 
Non-invasive & Non-intrusive. Unlike a blood or urine
tests, a breath test can be conducted almost anywhere,
anytime.
§ 
Can be done repeatedly without adverse effects, unlike
X-rays, which can lead to damage from radiation
exposure. § 
Relatively inexpensive
§ 
Rapid results
§ 
Proven technology with increase in breath-based tests
approved by the US Food and Drug Administration
(FDA)
EARLY SCREENING:
• HIGHER SURVIVAL RATES
• LOWER COST TO PATIENT AND INSURER
EARLY DETECTION AND
DISEASE SCREENING
• 
Breath testing has grown in popularity in recent years.
With evolving technologies in sampling, sensor design,
standardization, and analytical methods; breath analysis has the
potential to clinically benefit individuals on a global scale in the
future.
• 
Designed to screen for various illnesses before symptoms
appear, such as a tumor that appears when patients have a CT
scan, which means patients will have many more treatment
options available.
• 
Attractive benefits to both doctors and – non-invasive, painless,
having no side effects and available at an extremely low cost.
MEDICAL
APPLICATIONS
With most diseases, an early diagnosis means a better
prognosis, but sometimes it's difficult, painful and expensive
to test for illnesses. Now breath testing offers a new way to
spot a variety of conditions and all it takes is a simple
breath.
Breath testing offers diagnosis and monitoring of
§ 
Diabetes
§ 
Lung and breast cancer
§ 
Kidney and liver disease
§ 
Heart failure
§ 
Stomach problems and so much more
DISURPTIVE
TECHNOLOGY
"I think breath analysis is the new frontier and the future of
medical testing…"
Dr. Raed Dweik
Professor of Medicine & Director of the Breath Analysis Program at the
Cleveland Clinic.
"This is really a whole new field that has huge potential to
revolutionize the way we do medical testing and monitoring.
It has profound potential for global health."
"This is going to change medical diagnosis work,"
Professor Perena Gouma
Director of Stony Brook University's Center for Nanomaterials and Sensor
Development
"And that means a lot of better health and welfare, for
employers, for insurance, for physicians ... I think it's going to
have a great impact, and very soon.”
LUNG CANCER
DETECTION
§ 
A 2011 study reported that dogs had been trained to
reliably sniff out lung cancer in human breath.
§ 
Researchers have developed a breathalyzer that can
detect lung cancer and assess whether it is early or
advanced, according to findings presented at the
American Society of Clinical Oncology.
"We have almost 100 million smokers in the United States…if
we can do a one-off screening for lung cancer, that would
be incredibly impactful."
BREAST CANCER
§ 
Scientists have developed a breath test to check for
breast cancer.
§ 
Research shows the kit is at least as accurate as breast
X-rays routinely used in hospitals.
§ 
Breath test results are available immediately after test
administration
§ 
It may reduce the need for uncomfortable
mammograms and limit the radiation exposure during
testing
"A negative result on the breath test was especially useful,
because it ruled out both breast cancer and an abnormal
screening mammogram with almost 100% accuracy. Most
normal healthy woman will have a negative breath test
result, and they would probably not need a routine
screening mammogram.”
LIVER DISEASE
§ 
Breath testing for liver provides a safe, non-invasive
method of assessing liver function by continuously
measuring the by-product of 13C-methacetin
metabolism in the breath of test subjects.
§ 
The test also provides relatively accurate measure of
fibrosis and inflammation levels.
§ 
Breath testing for liver disease avoids traumatic liver
biopsy and blood tests.
“The new test could be used to assess prognosis from the
earliest stages of liver disease to cirrhosis, to help doctors
determine whether a cirrhotic patient has enough liver
function to undergo a surgical procedure, to prioritize
patients for liver transplantation, and perhaps to decide
when patients need to start therapy for chronic viral
hepatitis…”
Dr. Lalazar
DIABETES
§ 
Diabetes affects more than 171 million people
worldwide.
§ 
Diabetes may be characterised by elevated breath
acetone levels.
§ 
Even before blood tests are administered, people with
diabetes may be recognized of symptoms through
their breath acetone—a characteristic “fruity” odor
that increases significantly during periods of glucose
deficiency. Researchers are able to use this biomarker
as a possible diagnostic tool.
DIABETES
§ 
Current monitoring devices are mostly based on blood
glucose analysis. The development of alternative
devices that are noninvasive, inexpensive, and provide
easy-to-use breath analysis could completely change
the paradigm of self-monitoring diabetes.
§ 
The test works by detecting the harmful chemicals
called ‘ketones’ which accumulate in the body when
insulin levels are low.
“Currently testing for diabetes requires a blood test which
can be traumatic for children.”
HEART DISEASE
§ 
An experimental breath test, designed to quickly
identify patients suffering from heart failure has
demonstrated promise in early trials
§ 
Study teams have so far been able to correctly
diagnose heart failure among newly hospitalized
patients with a 100 percent accuracy.
§ 
The breath test correctly identified all the patients with
heart failure, clearly distinguishing them from those
cardiac cases where heart failure was not an issue.
BREATHTEC
BIOMEDICAL INC
§ 
Florida Corporation that has Option to acquire
University of Florida patent U.S. 8,237,118 entitled
“Partial Ovoidal FAIMS Electrode”.
§ 
University of Florida(UFL) patent is developed by Dr. Rick
Yost of the Yost Research Group at the UFL.
§ 
Research in the Yost group centers around three
aspects of analytical mass spectrometry:
instrumentation, fundamentals, and applications.
Instrumentation development includes a wide range of
projects in tandem mass spectrometry (MSn) and
chromatography.
§ 
Yost Research is utilizing high-field asymmetric
waveform ion mobility spectrometry (FAIMS) for the
analysis of various compounds and biomarkers.
YOST RESEARCH
GROUP-UFL
§ 
Led by Professor and Head of the Analytical Chemistry
Division- Rick Yost
§ 
Dr. Yost is the leading North American expert on mass
spectrometry and has served as the Treasurer and
Secretary of the American Society for Mass
Spectrometry
§ 
Dr. Yost has also served on the editorial boards of the
Journal of American Society for Mass Spectrometry and
the International Journal of Mass Spectrometry.
§ 
In 1993 Dr. Yost was the recipient of the American
Society of Mass Spectrometry Award for Distinguished
Contribution to Mass Spectrometry.
YOST RESEARCH
GROUP-UFL
§ 
Dr. Yost is recognized internationally as a leader in
the field of analytical chemistry, particularly mass
spectrometry. § 
Recipient of the 1993 ASMS Award for Distinguished
Contribution to Mass Spectrometry for the invention
and patent (along with Chris Enke) of the triple
quadruple mass spectrometer.
§ 
Over $20 Billion dollars of Dr. Yost’s tandem
quadruple mass spectrometers have been sold
worldwide
YOST RESEARCH
GROUP-UFL
§ 
Dr. Yost has supervised the research of over 90 graduate
students over the past 31 years, with funding totaling
over $10M from a wide range of sources (including NIH,
NSF, NASA, DoD, DHS and USDA).
§ 
The Yost Research Group at the University of Florida will
work in collaboration with Breathtec Biomedical Inc. to
design new portable hand held mass spectrometers for
use in medical settings to detect various illnesses. The
group has led to over 150 publications and 15 patents
§ 
The Yost Research Group at the University of Florida is
currently designing new portable instruments for
explosives detection and a novel laser microprobe for
mapping drugs and biomolecules in tissue specimens. Applications of their research range from biomedical to
environmental to forensic studies. BREATHTEC AGREEMENT
WITH UNIVERSITY OF FLORIDA
ON FAIMS TECHNOLOGY US PATENT 8,237,118
§ 
University of Florida Patent led by the Yost Research
Group and issued by US Patent Office in 2008.
§ 
FAIMS is a mass spectrometry technique that exploits
differences in ion mobility at very high electric fields,
to separate ions in the millisecond timescale after
liquid chromatography separation and prior to
introduction into the vacuum of a mass spectrometer.
§ 
FAIMS technology allows for miniaturization of mass
spectrometers and will enable hand held breath
testing devices to be developed
BREATHTEC
BIOMEDICAL
§ 
BreathTec is funding the Yost Research Group to
develop the University of Florida patent US PATENT
8,237,118 to develop hand held breath testing FAIMS
mass spectrometers for use in detecting various
illnesses thru breath
§ 
Initial focus of BreathTec will be to develop a breath
tests for detection of breast cancer, lung cancer,
diabetes and liver diseases.
BREATHTECH
INVESTMENT OPPORTUNITY
§ 
Current offering is 5 million shares at $0.20 per share.
§ 
Goal would be to get matching government grants
and develop hand held devices to breath testing
detection of cancers and certain other diseases.
§ 
Once devices are developed BreathTec would seek a
Stock Market listing in North America via an IPO or
Reverse Take Over.
MANAGEMENT
Kal Malhi, President, Director
Mr. Malhi is a Vancouver based entrepreneur and the founder
and President of Cannabix Technologies Inc. At Cannabix
Technologies Mr. Malhi has been instrumental in growing the
company from a startup to publicly traded company with a
current value in excess of $30 million dollars.
Mr. Malhi is a retired member of the Royal Canadian Mounted
Police and is also President of BullRun Group, a private
investment company specializing in early stage business
development.
MANAGEMENT
Dr. Raj Attariwala, MD, PhD., Lead Engineer
Dr. Attariwala is a Vancouver based dual board certified
Radiologist and Nuclear Medicine physician certified in
both Canada and the United States. He received his
formal medical training at University of British Columbia
with periods of specialized medical training at Memorial
Sloan Kettering Cancer Centre (New York), UCLA and USC.
He holds a doctorate in Biomedical Engineering from
Northwestern University (Evanston, IL).
Dr. Attariwala is a practicing physician in British Columbia
and is the owner of AIM medical imaging in Vancouver.
He has pioneered advances in the field of whole body
medical imaging thru his work and authored numerous
publications and presented at international medical
conferences on whole body imaging and cancer
detection. Dr. Attariwala is currently leading Breath
Testing for drug impairment at Cannabix Technologies Inc.
and has developed a breath testing system to test drivers
and employees for drug impairment.
MANAGEMENT
Dr. Rick Yost
Dr. Yost received his B.S. degree in Chemistry from the
University of Arizona in December 1974. In 1975 Dr. Yost
moved to pursue graduate studies in analytical chemistry
under an NSF graduate fellowship at Michigan State
University, focusing on electronics and computerized
instrumentation. Together with Professor Chris Enke, he
conceived of the computerized tandem quadruple mass
spectrometer for analytical MS/MS studies. This mass
spectrometer is currently in widespread use in the medical
field and has sales totalling over $20 Billion dollars.
Dr. Yost is a leading expert on mass spectrometry and has
lead the University of Florida Patent on FAIMS mass
spectrometry. Dr. Yost will guide the development of hand
held FAIMS mass spectrometers in collaboration with the
University of Florida and Breathtec Biomedical Inc.
CONTACT INFO
Kal Malhi
President
Breathtec Biomedical Inc.
[email protected]
604-805-4602